Immuno-Grade GLP1 Receptor Antibodies

The glucagon-like peptide-1 receptor (GLP1) is a class B G protein-coupled receptor that plays a crucial role in the regulation of glucose metabolism and energy balance. Pharmacologically, it is activated by the endogenous incretin hormone GLP-1 as well as by therapeutic agonists such as exenatide, liraglutide, semaglutide, and dulaglutide, which are widely used to treat type 2 diabetes and obesity. Upon ligand binding, GLP1 predominantly couples to Gs proteins, stimulating adenylate cyclase and increasing intracellular cyclic AMP, which in turn activates protein kinase A and Epac-dependent signaling pathways. These signaling cascades enhance glucose-dependent insulin secretion, inhibit glucagon release, slow gastric emptying, and promote pancreatic β-cell survival and proliferation. Additional signaling mechanisms, including β-arrestin recruitment and MAP kinase activation, contribute to receptor regulation and broader metabolic effects. GLP1 is most abundantly expressed in pancreatic β-cells but is also present in the brain, gastrointestinal tract, heart, and kidney, supporting its diverse physiological roles. Owing to its combined metabolic, cardiovascular, and appetite-regulating actions, GLP1 has become a major therapeutic target in modern metabolic disease management. For more information on GLP1 pharmacology please refer to the IUPHAR database. For further reading refer to:

Mayo KE, Miller LJ, Bataille D, Dalle S, Göke B, Thorens B, Drucker DJ. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev. 2003 Mar;55(1):167-94. doi: 10.1124/pr.55.1.6. PMID: 12615957.

Bataille D, Chan SL, Delagrange P, Drucker DJ, Göke B, Hills R, Mayo KE, Miller LJ, Salvatori R, Thorens B. Glucagon receptor family in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1).